Children's Hospital Research Center at Oakland

City University of New York

Kiverdi, Inc.

Children's Hospital & Research Institute at Oakland

Henrik Fyrst

Julie D Saba

Robert Bittman

John S Reed

Itzhak Kurek

Lisa Dyson

David J Galgoczy

Christer Jansson

Disclosed herein are microorganisms containing exogenous or heterologous nucleic acid sequences, wherein the microorganisms are capable of growing on gaseous carbon dioxide, gaseous hydrogen, syngas, or combinations thereof. In some embodiments the microorganisms are chemotrophic bacteria that produce or secrete at least 10% of lipid by weight. Also disclosed are methods of fixing gaseous carbon into organic carbon molecules useful for industrial processes. Also disclosed are methods of manufacturing chemicals or producing precursors to chemicals useful in jet fuel, diesel fuel, and biodiesel fuel. Exemplary chemicals or precursors to chemicals useful in fuel production are alkanes, alkenes, alkynes, fatty acid alcohols, fatty acid aldehydes, desaturated hydrocarbons, unsaturated fatty acids, hydroxyl acids, or diacids with carbon chains between six and thirty carbon atoms long. Also disclosed are microorganisms and methods using disclosed microorganisms for the production of butanediol and its chemical precursors in low-oxygen or anaerobic fermentation. Also disclosed are microorganisms and methods using disclosed microorganisms for generating hydroxylated fatty acids in microbes through the transfer of enzymes that are known to hydroxylate fatty acids in plants or microbes. Also disclosed are microorganisms and methods using disclosed microorganisms for the production of shorter-chain fatty acids in microbes through the introduction of exogenous fatty acyl-CoA binding proteins.

Engineered CO2-fixing chemotrophic microorganisms producing carbon-based products and methods of using the same

Methods are provided for producing omega-7 fatty acids from feedstock that includes syngas usingmicroorganisms. The syngas feedstock includes at least one of CO or a mixture of COand H, and the methods include introducing syngas into a bioreactor, where chemoautotrophicmicroorganisms convert the gaseous feedstock into omega-7 fatty acids, such as palmitoleic acid and vaccenic acid.

Methods of using natural and engineered organisms to produce small molecules for industrial application

The present invention is directed to unsaturated sphingosine compounds which are useful as therapeutic agents for the treatment of cancer and for the treatment of other diseases including diabetes and infection with intracellular bacteria. The invention is also directed to methods of using the compounds and pharmaceutical compositions comprising the compounds in treating these diseases.

Use of unsaturated sphingosine compounds as chemotherapeutic agents for the treatment of cancer

The present invention is directed to unsaturated sphingosine compounds which are useful as therapeutic agents for the treatment of cancer and for the treatment of other diseases including diabetes and infection with intracellular bacteria. This invention is also directed to methods of using the compounds and pharmaceutical compositions comprising the compounds in treating these diseases.

Compositions, methods and kits for diagnosing and treating cancer and muscular disorders are provided. Therapeutic compositions may comprise agents that modulate sphingolipid metabolism and/or signaling pathways. Such compositions may be administered to a mammal afflicted with cancer. Diagnostic methods and kits may employ an agent suitable for detecting alterations in endogenous genes involved in sphingolipid metabolism. Such methods and kits may be used to detect the presence of a cancer or to evaluate the prognosis of a known disease. SPL polypeptides, polynucleotides and antibodies are also provided.

Compositions and methods for the modulation of sphingolipid metabolism and/or signaling

Compositions, methods and kits for diagnosing and treating cancer are provided. Therapeutic compositions may comprise agents that modulate the expression or activity of a sphingosine-1-phosphate lyase (SPL). Such compositions may be administered to a mammal afflicted with cancer. Diagnostic methods and kits may employ an agent suitable for detecting alterations in endogenous SPL. Such methods and kits may be used to detect the presence of a cancer or to evaluate the prognosis of a known disease. SPL polypeptides, polynucleotides and antibodies are also provided.

Growing community of inventors

Oakland, CA, United States of America

Henrik Fyrst